› Forums › Cutaneous Melanoma Community › Yervoy/prostate cancer
- This topic is empty.
- Post
-
- September 12, 2013 at 12:05 pm
Bristol-Myers Squibb Co. (BMY) on Thursday said its test to see if a skin-cancer drug can be used to treat prostate cancer didn't achieve its primary endpoint in a late-stage trial.
The pharmaceutical company was testing the efficacy of Yervoy after radiation in patients with advanced metastatic castration-resistant prostate cancer.
The company did observe some positive results across some efficacy endpoints, particularly in patients with a less-advanced form of the cancer.
"These results offer important insights for ongoing and future studies of Yervoy in prostate cancer, including a second large trial of Yervoy in patients with less-advanced disease," said W.R. Gerritsen, of Radboud University Nijmegen Medical Centre in the Netherlands.
Yervoy, currently approved in more than 40 countries to treat patients with melanoma, has been one of Bristol-Myers' successful newer drugs. However, revenue from the newer products hasn't helped the company stave off increased competition from generics. In July, the company reported a 17% drop in second-quarter profits.
Tagged: cutaneous melanoma
- You must be logged in to reply to this topic.